Last reviewed · How we verify
NCT06198465
Perioperative Adebrelimab and Chemotherapy in Esophageal and Esophagogastric Junction Carcinoma
Phase 2 trial testing adebrelimab,Paclitaxel,Lobaplatin,Fluorouracil in Adebrelimab in 24 participants. Status unknown.
30 December 2024
Quick facts
| Lead sponsor | Xijing Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 30 March 2024 |
| Primary completion | 30 December 2024 |
| Estimated completion | 30 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- adebrelimab,Paclitaxel,Lobaplatin,Fluorouracil — full drug profile →
Conditions studied
- Adebrelimab — all drugs for Adebrelimab →
- Esophageal Cancer — all drugs for Esophageal Cancer →
- Perioperative Period — all drugs for Perioperative Period →
Sponsor
Xijing Hospital
Who can join
18 and older, any sex, with Adebrelimab or Esophageal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this prospective, open-label, single-center clinical study is to learn about the efficacy and safety of aderbelimab combined with chemotherapy in the perioperative treatment of esophageal and esophagogastric junction cancer. The main question it aims to answer are:prediction for pCR after perioperative adebrelimab and chemotherapy in esophageal and esophagogastric junction carcinoma
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Neoadjuvant adebrelimab combined with triplet chemotherapy for locally advanced resectable adenocarcinoma of esophagogastric junction: a prospective, single-arm, phase II feasibility and safety study.
Liu J, Zhang R, Zhou W, Li Z, et al · · 2026 · PMID 42169915 · DOI 10.21037/jgo-2026-0236
Verify or expand the search:
- PubMed search for NCT06198465
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Adebrelimab
Currently open trials in the same condition.
- NCT07353684 — Adebrelimab, Apatinib & SOX for Conversion Therapy in Advanced Gastric/GEJ Cancer · Phase 2 · recruiting
- NCT06405061 — Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectabl · Phase 2 · recruiting
- NCT05970666 — Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocell · Phase 2 · recruiting
Other Xijing Hospital trials
Trials by the same sponsor.
- NCT07532096 — Extended Sentinel Lymph Node Biopsy With Methylene Blue Single Tracer Post-Neoadjuvant Therapy for Node-Positive Breast · NA · not yet recruiting
- NCT07519018 — TIS for Drug Resistant TLE · NA · not yet recruiting
- NCT07518992 — Correlation Between Preoperative Sleep and Postoperative Brain and Renal Dysfunction · not yet recruiting
- NCT07466303 — Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07474142 — A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve P · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06198465 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xijing Hospital
- Last refreshed: 10 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06198465.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing